CAS:178616-26-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Array ( [133] => Array ( [id] => 133 [name] => Inhibitors & Antagonists & Agonists [children] => Array ( [352] => Array ( [id] => 352 [name] => Protein Tyrosine Kinase/PTK ) [350] => Array ( [id] => 350 [name] => PI3K/Akt/mTOR ) [351] => Array ( [id] => 351 [name] => Endocrinology & Hormones ) [357] => Array ( [id] => 357 [name] => Angiogenesis ) [358] => Array ( [id] => 358 [name] => HIF ) [363] => Array ( [id] => 363 [name] => Immunology & Inflammation ) [364] => Array ( [id] => 364 [name] => Stem Cells ) [365] => Array ( [id] => 365 [name] => Apoptosis ) [377] => Array ( [id] => 377 [name] => Metabolic Enzyme & Protease ) [379] => Array ( [id] => 379 [name] => Autophagy ) [380] => Array ( [id] => 380 [name] => ER Stress ) [384] => Array ( [id] => 384 [name] => Cell Cycle ) [385] => Array ( [id] => 385 [name] => Cytoskeleton ) [386] => Array ( [id] => 386 [name] => DNA Damage & DNA Repai ) [387] => Array ( [id] => 387 [name] => Epigenetics ) [388] => Array ( [id] => 388 [name] => Ubiquitin ) [389] => Array ( [id] => 389 [name] => JAK/STAT ) [390] => Array ( [id] => 390 [name] => GPCR & G Protein ) [391] => Array ( [id] => 391 [name] => Neuronal Signal Pathway ) [392] => Array ( [id] => 392 [name] => MAPK ) [393] => Array ( [id] => 393 [name] => NF-κB ) [394] => Array ( [id] => 394 [name] => Membrane Transporter & Ion Channel ) [395] => Array ( [id] => 395 [name] => TGF-β/Smad ) [396] => Array ( [id] => 396 [name] => Hippo ) [775] => Array ( [id] => 775 [name] => Antibody-drug Conjugate/ADC Related ) [122] => Array ( [id] => 122 [name] => Others ) ) [num] => Array ( [0] => Array ( [count(*)] => 2140 ) ) ) )
>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Membrane Transporter & Ion Channel >
CFM-2CAS:178616-26-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
CAS | 178616-26-7 |
English Name | CFM-2 |
Synonyms | ;HQ-495;CFM-2 |
Molecular Formula | C17H17N3O3 |
Molecular Weight | 311.34 |
Solubility | Soluble in DMSO(Need ultrasonic) |
Purity | ≥98% |
Appearance | Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
SMILES | COC1=C(C=C2C(=C1)CC(=O)NN=C2C3=CC=C(C=C3)N)OC |
InChIKey | MJKADKZSYQWGLL-UHFFFAOYSA-N |
InChI | InChI=1S/C17H17N3O3/c1-22-14-7-11-8-16(21)19-20-17(13(11)9-15(14)23-2)10-3-5-12(18)6-4-10/h3-7,9H,8,18H2,1-2H3,(H,19,21) |
PubChem CID | 4377504 |
Target Point | AMPAR |
Passage | Membrane Transporter&Ion Channel;Neuronal Signaling |
Background | CFM-2 is a non-competitive inhibitor of choice for AMPAR. |
Biological Activity | CFM-2 是一直能够选择性福 AMPA 受体拮抗剂,在癫痫发作模型中具有抗惊厥活性。[1-3] |
In Vivo | Pretreatment with CFM-2(20 or 50 micromol /kg,i.p.)delayed the progression of seizure rank of pentylentetrazole induced kindling in rats. CFM-2(15 or 30 days,repeated treatment)were significantly protected against seizures induced by pentylentetrazole or picrotoxin.[1] Intrathecal application of two selective non-competitive AMPAR antagonists,CFM-2(25 and 50 microg)and GYKI 52466(50 microg),significantly attenuated mechanical and thermal hypersensitivities on the ipsilateral hind paw at 2 and 24 h post-CFA injection.[3] |
Data Literature Source | [1]. De Sarro G,et al. Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur J Pharmacol. 1999 Mar 5;368(2-3):149-59. [2]. Rizzo M,et al. Determination of new 2,3-benzodiazepines in rat plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):207-15. [3]. Rizzo M,et al. Determination of new 2,3-benzodiazepines in rat plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):207-15. |
Unit | Bottle |
Specification | 10mg |